How Has the HERG Screening Market Evolved Historically and What is its Current Size?
The herg screening market has seen considerable growth due to a variety of factors.
• Recent years have seen a quick expansion in the size of the HERG screening market. Projected to rise from $1.62 billion in 2024 to $1.84 billion in 2025, this market demonstrates a compound annual growth rate (CAGR) of 13.9%.
The growth observed during the historic period is largely due to the rise in pharmaceutical advancements, regulatory standards, increased consciousness concerning heart health, and a growing occurrence of heart-related ailments.
What Is The Projected Growth Of The HERG Screening Template Market?
The herg screening market is expected to maintain its strong growth trajectory in upcoming years.
• Over the next few years, a swift expansion is anticipated for the HERG screening market, predicted to reach a worth of $2.9 billion by 2029, coming to represent a compound annual growth rate (CAGR) of 12.0%.
The projected growth in this period can largely be linked to the increasing embrace of personalized medicine, a surge in drug development activities being outsourced, the rise of emerging research markets, as well as a heightened emphasis on non-cardiac safety evaluations. Key trends in this forecast period comprise improvements in in vitro models, concerted efforts in combining genomic and proteomic data, progress in computational methodologies, a focus on the safety of pediatric drugs, and partnerships encouraging the standardization and sharing of data.
What Are The Key Drivers Fueling Growth In The HERG Screening Market?
The HERG screening market's exponential growth is largely attributed to the increasing number of patients suffering from heart disorders. These disorders, also commonly referred to as cardiovascular diseases, encompass an array of conditions impacting the heart and blood vessels. Such conditions contribute to impaired heart functioning and pose serious health risks. Risk factors leading to these disorders involve unhealthy lifestyle choices, an aging population, genetic predispositions, diabetes, and metabolic syndrome. By employing HERG screening, potential drug candidates can be identified to prevent severe cardiac occurrences that could result in fatal cardiac arrhythmias, particularly torsade de pointes (TdP), thereby enhancing the patient's health prognosis. For example, as per a May 2023 report compiled by the Centers for Disease Control and Prevention, a public health entity based in the US, cardiovascular diseases affected 1 in 20 adults aged 20 and over, with about 695,000 people grappling with these diseases, leading to 375,476 fatalities. Also, a report furnished by the Office for National Statistics, a governmental entity based in the UK, showed that heart attacks claimed the lives of 20,061 individuals in March 2022, marking an annual increase. Consequently, the growth of the HERG screening market is being propelled by the escalated numbers of patients diagnosed with heart disorders.
What Are The Principal Market Segments In The Global HERG Screening Industry?
The HERG screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Subsegmeents:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations
Pre-Book The HERG Screening Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The HERG Screening Market?
Leading firms in the HERG screening market are focusing on the integration of innovative advanced solutions like GLP-certified HERG screening services to boost cardiac safety evaluations during the drug development process. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) through the traditional whole-cell patch-clamp method. This method ensures the screening aligns with regulatory protocols such as ICH S7A and ICH S7B which are crucial for safety pharmacology studies during the drug development stage. An illustration of this is when Metrion Biosciences Ltd., a pharmaceutical company based in the UK, introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. The aim of this service is to amplify Metrion's assistance for the development of small molecule therapeutics and supplement the company's existing cardiac safety services. Furthermore, this service employs the traditional whole-cell patch-clamp method to determine potential cardiac risks before initiating Phase 1 human clinical trials, offers regulatory advice for safety pharmacology studies in drug development, as well as providing clients with quality biology services for ion channel targets.
Who Are the Key Players In The HERG Screening Market?
Major companies operating in the HERG screening market are:
• Eurofins-Cerep SA.
• Aviva Biosciences Inc.
• AstraZeneca Public Limited Company
• Merck KGaA
• Charles River Laboratories Inc.
• Abcam Public Limited Company
• Molecular Devices LLC
• Caliper Life Sciences Inc.
• Crprotex Limited
• ChanTest Corporation
• Creative bioarray Inc.
• Cellular Dynamics International Inc.
• Nanion Technologies
• Essen Bioscience
• ABR-Affinity BioReagents Inc.
• ACEA Biosciences Inc.
• Metrion biosciences Inc.
• Aurora Biomed Inc.
• Aureus Sciences
• RedShift BioAnalytics
• B'SYS GmbH
• Cambridge Bioscience Ltd.
• Sophion Bioscience Inc.
• Fluxion Biosciences Inc.
• ChemAxon Ltd.
What Are The Regional Insights Into The HERG Screening Market?
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
